Opioid Adverse Effects and Opioid-Induced Hypogonadism

Chapter

Abstract

Opioids are potent pain relievers and have been used as analgesics for centuries. Unfortunately, adverse effects related to opioids may result in discontinuation of these medications and other potentially worse outcomes. An understanding of the major adverse effects of opioids as well as knowledge of how to evaluate and manage these adverse effects will improve a physician’s ability to successfully treat patients requiring opioids. In this chapter, we will review opioid-related nausea and vomiting, constipation, neuroendocrine effects, immune effects, respiratory depression, central nervous system effects, and pruritis.

Keywords

Osteoporosis Tuberculosis Serotonin Testosterone Histamine 

References

  1. 1.
    More RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther. 2005;7(5):R1046–51.CrossRefGoogle Scholar
  2. 2.
    Kalso E, Allan L, Dellemijn PLI, Faura CC, Ilias WK, Jensen TS, Perrot S, Plaghki LH, Zenz M. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain. 2003;7(5):381–6.PubMedCrossRefGoogle Scholar
  3. 3.
    O’Mahony S, Coyle N, Payne R. Current management of opioid related side effects. Oncology. 2001;15(1):61–74.PubMedGoogle Scholar
  4. 4.
    Herndon CM, Jackson 2nd KC, Hallin PA. Management of opioid-induced gastrointestinal effects in patients receiving palliative care. Pharmacotherapy. 2002;22(2):240–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Okamoto Y, Tsuneto S, Matsuda Y, et al. A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage. 2007;34:217–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Porreca F, Ossipov MH. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med. 2009;10(4):654–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician. 2006;74:1347–54.PubMedGoogle Scholar
  8. 8.
    Moss J, Rosow CE. Development of peripheral opioid antagonists’ new insights into opioid effects. Mayo Clin Proc. 2008;83(10):1116–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Harris JD. Management of expected and unexpected opioid-related side effects. Clin J Pain. 2008;24 Suppl 10:S8–13.PubMedCrossRefGoogle Scholar
  10. 10.
    Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol and marijuana. Ann Intern Med. 1997;126(10):791–8.PubMedGoogle Scholar
  11. 11.
    Lee A, Fan LT. Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2010;(2):CD003281.Google Scholar
  12. 12.
    Bao T. Use of acupuncture in the control of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw. 2009;7(5):606–12.PubMedGoogle Scholar
  13. 13.
    Mansky PJ, Wallerstedt DB. Complementary medicine in palliative care and cancer symptom management. Cancer J. 2006;12(5):425–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Scorza K, Williams A, Phillips D, Shaw J. Evaluation of nausea and vomiting. Am Fam Physician. 2007;76(1):76–84.PubMedGoogle Scholar
  15. 15.
    Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480–91.PubMedCrossRefGoogle Scholar
  17. 17.
    Fox-Threlkeld JE, Daniel EE, Christinck F, Hruby VJ, Cipris S, Woskowska Z. Identification of mechanisms and sites of actions of mu and delta opioid receptor activation in the canine intestine. J Pharmacol Exp Ther. 1994;268(2):689–700.PubMedGoogle Scholar
  18. 18.
    Holzer P. Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett. 2004;361(1–3):192–5.PubMedCrossRefGoogle Scholar
  19. 19.
    De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil. 2004;16(4):383–94.PubMedCrossRefGoogle Scholar
  20. 20.
    Canty SL. Constipation as a side effect of opioids. Oncol Nurs Forum. 1994;21:739–45.PubMedGoogle Scholar
  21. 21.
    Michael AA, Arthur GL, Daniel C, Carla R. Principles of analgesic use in the treatment of acute pain and cancer pain. 5th ed. Glenview: American Pain Society; 2003.Google Scholar
  22. 22.
    Clemens KE, Klaschik E. Management of constipation in palliative care patients. Curr Opin Support Palliat Care. 2008;2(1):22–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Likar R. Transdermal buprenorphine in the management of persistent pain – safety aspects. Ther Clin Risk Manag. 2006;2:115–25.PubMedGoogle Scholar
  24. 24.
    Bach V, Kamp-Jensen M, Jensen N-H, Eriksen J. Buprenorphine and sustained release morphine – effects and side effects in chronic use. Pain Clin. 1991;4:87–93.Google Scholar
  25. 25.
    Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ. 2001;322(7295):1154–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Arce DA, Ermocilla CA, Costa H. Evaluation of constipation. Am Fam Physician. 2002;65(11):2283–90.PubMedGoogle Scholar
  27. 27.
    Daniell HW. Hypogonadism in men consuming sustained-action opioids. J Pain. 2002;3(5):377–84.PubMedCrossRefGoogle Scholar
  28. 28.
    Cicero TJ. Effects of exogenous and endogenous opiates on the hypothalamic–pituitary–gonadal axis in the male. Fed Proc. 1980;39(8):2551–4.PubMedGoogle Scholar
  29. 29.
    Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008;9(1):28–36.PubMedCrossRefGoogle Scholar
  30. 30.
    Genazzani AR, Genazzani AD, Volpogni C, et al. Opioid control of gonadotropin secretion in humans. Hum Reprod. 1993;8 suppl 2:151–3.PubMedCrossRefGoogle Scholar
  31. 31.
    Jordan D, Tafani JA, Ries C, Zajac JM, Simonnet G, Martin D, Kopp N, Allard M. Evidence for multiple opioid receptors in the human posterior pituitary. J Neuroendocrinol. 1996;8(11):883–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Cicero TJ, Bell RD, Wiest WG, et al. Function of the male sex organs in heroin and methadone users. N Engl J Med. 1975;292:882–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Kaminski T. The involvement of protein kinases in signalling of opioid agonist FK 33-824 in porcine granulosa cells. Anim Reprod Sci. 2006;91:107–22.PubMedCrossRefGoogle Scholar
  34. 34.
    Vuong C, Van Uum SH, O’Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31(1):98–132.PubMedCrossRefGoogle Scholar
  35. 35.
    AACE Hypogonadism Task Force. American association of clinical endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002;8(6):439–56.Google Scholar
  36. 36.
    Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone patch therapy in men with opioid induced androgen deficiency (OPIAD). J Pain. 2006;7:200–10.PubMedCrossRefGoogle Scholar
  37. 37.
    Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009;25(2):170–5.PubMedCrossRefGoogle Scholar
  38. 38.
    Daniell HW. DHEAS deficiency during consumption of sustained-action prescribed opioids: evidence for opioid- induced inhibition of adrenal androgen production. J Pain. 2006;7:901–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Rothman MS, Wierman ME. Female hypogonadism: evaluation of the hypothalamic-pituitary-ovarian axis. Pituitary. 2008;11:163–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005;174(3):827–34.PubMedCrossRefGoogle Scholar
  41. 41.
    Cantacuzene. Annales de L’Institut Pasteur. 1898; xli:273.Google Scholar
  42. 42.
    Kraft A, Leitch NM. The action of drugs in infection I. The influence of morphine in experimental septicemia. J Pharmacol Exp Ther. 1921;5:3877–84.Google Scholar
  43. 43.
    Roy S, Loh HH. Effects of opioids on the immune system. Neurochem Res. 1996;21(11):1375–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Mellon RD, Bayer BM. Evidence for central opioid receptors in the immunomodulatory effects of morphine: review of potential mechanism(s) of action. J Neuroimmunol. 1998;83(1–2):19–28.PubMedCrossRefGoogle Scholar
  45. 45.
    Peterson PK, Molitor TW, Chao CC. Mechanisms of morphine-induced immunomodulation. Biochem Pharmacol. 1993;46:343–8.PubMedCrossRefGoogle Scholar
  46. 46.
    Roy S, Wang J, Kelschenbach J, Koodie L, Martin J. Modulation of immune function by morphine: implications for susceptibility to infection. J Neuroimmune Pharmacol. 2006;1:77–89.PubMedCrossRefGoogle Scholar
  47. 47.
    Shavit Y, Ben-Eliyahu S, Zeidel A, Beilin B. Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats dose and timing study. Neuroimmunomodulation. 2004;11(4):255–60.PubMedCrossRefGoogle Scholar
  48. 48.
    Beilin B, Shavit Y, Hart J, Mordashov B, Cohn S, Notti I, Bessler H. Effects of anesthesia based on large versus small doses of fentanyl on natural killer cell cytotoxicity in the perioperative period. Anesth Analg. 1996;82(3):492–7.PubMedGoogle Scholar
  49. 49.
    Sacerdote P, Manfredi B, Mantegazza P, Panerai AE. Antinociceptive and immunosuppressive effects of opiate drugs: a structure-related activity study. Br J Pharmacol. 1997;121(4):834–40.PubMedCrossRefGoogle Scholar
  50. 50.
    Martucci C, Panerai AE, Sacerdote P. Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses. Pain. 2004;110(1–2):385–92.PubMedCrossRefGoogle Scholar
  51. 51.
    Sacerdote P. Opioids and the immune system. Palliat Med. 2006;20 Suppl 1:s9–15.PubMedGoogle Scholar
  52. 52.
    Budd K. Pain management: is opioid immunosuppression a clinical problem? Biomed Pharmacother. 2006;60(7):310–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Sacerdote P. Opioid-induced immunosuppression. Curr Opin Support Palliat Care. 2008;2(1):14–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract. 2008;8(4):287–313.PubMedCrossRefGoogle Scholar
  55. 55.
    Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226–38.PubMedCrossRefGoogle Scholar
  56. 56.
    McNicol E, Horowicz-Mehler N, Fisk RA, Bennett K, Gialeli-Goudas M, Chew PW, Lau J, Carr D. Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review. J Pain. 2003;4(5):231–56.PubMedCrossRefGoogle Scholar
  57. 57.
    Mueller RA, Lundberg DB, Breese GR, Hedner J, Hedner T, Jonason J. The neuropharmacy of respiratory control. Pharmacol Rev. 1982;34:255–85.PubMedGoogle Scholar
  58. 58.
    Olofsen E, van Dorp E, Teppema L, Aarts L, Smith TW, Dahan A, Sarton E. Naloxone reversal of morphine- and morphine-6-glucuronide-induced respiratory depression in healthy volunteers: a mechanism-based pharmacokinetic-pharmacodynamic modeling study. Anesthesiology. 2010;112(6):1417–27.PubMedCrossRefGoogle Scholar
  59. 59.
    Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153–93.PubMedCrossRefGoogle Scholar
  60. 60.
    Lerma EV, Berns JS, Nissenson AR. Current diagnosis & treatment: nephrology & hypertension. New York: The McGraw-Hill Companies; 2009. p. 58.Google Scholar
  61. 61.
    Christo PJ. Opioid effectiveness and side effects in chronic pain. Anesthesiol Clin North America. 2003;21(4):699–713.PubMedCrossRefGoogle Scholar
  62. 62.
    Reissig JE, Rybarczyk AM. Pharmacologic treatment of opioid-induced sedation in chronic pain. Ann Pharmacother. 2005;39:727–31.PubMedCrossRefGoogle Scholar
  63. 63.
    Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain. 1989;39(1):13–6.PubMedCrossRefGoogle Scholar
  64. 64.
    Byas-Smith MG, Chapman SL, Reed B, Cotsonis G. The effect of opioids on driving and psychomotor performance in patients with chronic pain. Clin J Pain. 2005;21(4):345–52.PubMedCrossRefGoogle Scholar
  65. 65.
    Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Can patients taking opioids drive safely? A structured evidence-based review. J Pain Palliat Care Pharmacother. 2002;16(1):9–28.PubMedCrossRefGoogle Scholar
  66. 66.
    Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Are opioid-dependent/tolerant patients impaired in driving-related skills? A structured evidence-based review. J Pain Symptom Manage. 2003;25(6):559–77.PubMedCrossRefGoogle Scholar
  67. 67.
    Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V, Expert Working Group of the European Association of Palliative Care Network. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9):2542–54.PubMedGoogle Scholar
  68. 68.
    Ballantyne JC, Loach AB, Carr DB. Itching after epidural and spinal opiates. Pain. 1988;33(2):149–60.PubMedCrossRefGoogle Scholar
  69. 69.
    Chaney MA. Side effects of intrathecal and epidural opioids. Can J Anaesth. 1995;42(10):891–903.PubMedCrossRefGoogle Scholar
  70. 70.
    Ganesh A, Maxwell LG. Pathophysiology and management of opioid-induced pruritus. Drugs. 2007;67(16):2323–33.PubMedCrossRefGoogle Scholar
  71. 71.
    Szarvas S, Harmon D, Murphy D. Neuraxial opioid-induced pruritus: a review. J Clin Anesth. 2003;15(3):234–9.PubMedCrossRefGoogle Scholar
  72. 72.
    Diego L, Atayee R, Helmons P, von Gunten CF. Methylnaltrexone: a novel approach for the management of opioid-induced constipation in patients with advanced illness. Expert Rev Gastroenterol Hepatol. 2009;3(5):473–85.PubMedCrossRefGoogle Scholar
  73. 73.
    Kjellberg F, Tramèr MR. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. Eur J Anaesthesiol. 2001;18(6):346–57.PubMedGoogle Scholar
  74. 74.
    Jiang YH, Jiang W, Jiang LM, Lin GX, Yang H, Tan Y, Xiong WW. Clinical efficacy of acupuncture on the morphine-related side effects in patients undergoing spinal-epidural anesthesia and analgesia. Chin J Integr Med. 2001;16(1):71–4.CrossRefGoogle Scholar

Copyright information

© American Academy of Pain Medicine 2013

Authors and Affiliations

  1. 1.Rehabilitation & Pain SpecialistsPittsburghUSA
  2. 2.Department of AnesthesiologyPennsylvania State University College of MedicineHersheyUSA

Personalised recommendations